Pediatric multiple sclerosis (MS) with onset before age 18 years represents up to 10% of patients with MS.^[@R1]^ Overall progression of disease, which often has a relapsing-remitting course in children, is slow compared with adults.^[@R2]^ However, irreversible disability is reached 10 years sooner.^[@R3]^ By age 35 years, half of pediatric patients with MS have had secondary progression of disease.^[@R1]^

Chronic, disabling neurologic diseases carry a high burden of health care costs and resource utilization. Pediatric patients with neurologic impairments account for 29% of charges at children\'s hospitals.^[@R4]^ Per-patient health care costs in adult-onset MS are estimated at \$34,000 annually and \$2.2 million over a lifetime.^[@R5]^ We established a population-based cohort of pediatric MS patients in order to determine the burden of health care costs for patients and families.

METHODS {#s1}
=======

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

The University of Utah\'s and Intermountain Healthcare (IH)\'s Institutional Review Boards approved this retrospective database and chart review study; informed consent was waived.

Cohort identification. {#s1-2}
----------------------

IH is a large, not-for-profit health care system in the Intermountain West containing over 185 clinics and 22 hospitals, including the only children\'s hospital in Utah. IH maintains records of hospital, emergency department, clinic, laboratory, pharmacy, and home health visits in an electronic record format. A cohort of all patients with pediatric MS presenting between 2002 and 2012 was compiled; follow-up and inclusion of cost data were through December 31, 2013. Cases were identified through a computerized search of diagnosis codes related to demyelinating diseases (ICD-9 323.82, 340.x, 341.x, 377.3, 323.x). Patients who met McDonald diagnostic criteria for diagnosing pediatric MS were included and verified by manual chart review.^[@R6]^ Chart review was conducted by one researcher (M.A.W.) and confirmed by a reviewer (M.S.C.) with a second reviewer (J.L.B.) available to address discrepancies when needed.

Incidence. {#s1-3}
----------

The cohort included all infants born in Utah between 1985 and 2012. Annual birth rates were utilized to estimate the total population count. Life table method analysis was used to calculate the hazard rate of MS by each year of age as well as the overall incidence. Left truncation was used to ensure accurate risk sets at each year.

Cost and encounter data. {#s1-4}
------------------------

IH maintains an Enterprise Data Warehouse (EDW), which contains financial data for patient encounters. The EDW was queried using unique identifiers for each patient to obtain comprehensive cost information pertaining to imaging, laboratory, pharmacy, clinic visits, hospital stays, and amount of time spent receiving care. Costs were categorized by type (diagnostics, therapeutics, room overhead) as well as by setting (outpatient, inpatient, emergency department), and were adjusted to 2014 US dollars (see Nelson et al.^[@R7]^ for detailed definitions of cost groups). The EDW does not maintain data for professional practitioner fees, which were therefore not included in total costs. Lost days were defined by total number of days spent receiving care during the 10-year period.

Cost groups. {#s1-5}
------------

The cohort was ordered by total cost per patient, with the top 16th percentile of patients identified as the high-cost group and the bottom 84th percentile representing the low-cost group. Differences in demographics and health care burden data between the cost groups were compared. Two-tailed *p* values were calculated using unpaired *t* test or Fisher exact test.

RESULTS {#s2}
=======

Incidence and demographics. {#s2-1}
---------------------------

We identified 57 pediatric patients with MS treated at an IH facility between 2002 and 2012. The annual mean incidence of pediatric MS in Utah was 0.57 cases per 100,000 pediatric population, with a prevalence of 4.65 per 100,000. Demographic information is summarized in [table 1](#T1){ref-type="table"}.

###### 

Demographic and clinical characteristics of the pediatric multiple sclerosis cohort
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Health care burden. {#s2-2}
-------------------

Total costs for the cohort over the 10-year period amounted to greater than \$1.5 million. The majority of costs came from outpatient care, accounting for \$1,256,969, or 83.1% of total costs. Inpatient expenses represented 13.6%, with emergency department visits adding only 3.3%. Inpatient visits were more costly at \$2,924 per encounter. When cost was divided by type, room overhead charges were the largest source, totaling \$701,642 or 46.4%. Therapy and diagnostic expenditures accounted for 27.9% and 25.7%, respectively ([table 2](#T2){ref-type="table"}).

###### 

Health care costs by setting and type
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A high-cost group, consisting of the 9 patients whose costs made up the top 16% of the cohort, incurred 63% of total costs. The mean cost of medical care per patient in this group was \$105,166, compared to \$11,778 in the low-cost group. Across all settings, mean costs per encounter were higher for the high-cost group (\$1,255 vs \$772). Over the study period, the entire cohort lost 6,092 total days of work/school/potential productivity. High-cost patients averaged 107 lost days, with low-cost patients averaging half that amount. The number of encounters totaled 1,486, with a mean of 84 encounters per high-cost patient and 15 per low-cost patient. The high-cost group averaged 12 MRIs per patient compared to 5 in the low-cost group ([table 3](#T3){ref-type="table"}).

###### 

Burden of health care for pediatric patients with multiple sclerosis and their families
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DISCUSSION {#s3}
==========

This study evaluates the burden and cost of health care for pediatric patients with MS. Outpatient services were the primary contributor to costs. Inpatient stays, although a smaller proportion of total costs, were 3 times as expensive in their average cost per encounter. The indirect burden of health care for families was apparent, with patients spending an average of 10 days per year receiving medical care. Our population-based cohort\'s incidence of pediatric MS was similar to previous reports.^[@R8]^

A minority of the patient cohort accounted for the majority of cost. The high-cost group had statistically more encounters per patient, and, in particular, more outpatient visits. The definition of a high-cost group is based on prior cost studies with skewed (non-normal) distributions.^[@R7],[@R9]^ High-cost patients averaged higher costs per encounter, more MRIs, a greater number of days spent receiving care, and had a longer average length of time in the study. It is unclear whether extending the study period would result in the same disparities.

Sex, race, age at onset, and length of time to diagnosis were not predictive of cost group. Clinical characteristics of patients were analyzed, but underpowered to reveal significant differences between groups. It is not clear whether greater health care costs for the high-cost cohort relate to disease severity and a need for closer management or to overutilization of resources. Future studies can address whether the high-cost group represented a distinct pediatric MS disease subtype or had other features accounting for the more severe course.

A limitation of this study is that the cost totals do not include costs for physician services. Costs described are those applied to patients by the health care system, and do not account for insurance coverage. They also do not include indirect and out-of-pocket costs, such as those associated with travel to appointments or lost wages, which families of pediatric patients with MS are likely to incur. Our study represents a single health care system (IH) over a 10-year period. While a significant majority of specialty pediatric health care in Utah (\>90%) is provided through IH, we cannot comment on the potential costs of health care services obtained outside of IH. While Utah\'s outmigration rate is among the lowest in the United States,^[@R10]^ patients may have moved out of the state and been lost to follow-up. The data are affected by the varying duration of time each patient spent in the study. Our analysis did not use any imputed data or last results carried forward approach. Thus, while it could not model a complete longitudinal history of pediatric MS costs, it provides specific concrete values. We included cost data from patients who were pediatric (age \<19) at presentation but who, during the course of data collection (2002--2013), may have aged out. As such, our reported costs likely underestimate the actual health care burden.

Although costs for pediatric patients with MS are less than those found in similar studies of adults,^[@R5]^ the costs represent only the earliest stages of a chronic, progressive disease. While pediatric MS is associated with slower progression, it has earlier onset of disability. These data represent only a small proportion of the costs that the cohort will incur over a lifetime. Given the high cost of inpatient encounters, efforts to maintain efficient, high-quality outpatient management and avoid hospital stays may be a means of effective cost control and improved patient care.
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